A Comparative Study of KES524 in Patients With Obesity Disease
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of KES524 in patients with obesity (visceral fat
obesity with type 2 diabetes and dyslipidemia), a 52-week, double-blind, placebo-controlled
comparative study is conducted. This study aims to examine superiority of KES524 to placebo
by employing change and percent change in body weight (primary endpoints) and changes in
proportion of subjects achieving ≧ 5% weight reduction, BMI, waist circumference, visceral
fat area, subcutaneous fat area, V/S ratio by abdominal CT scan, HbA1c, TG and HDL-C
(secondary endpoints).